24 74

Cited 0 times in

Rifabutin Is Active against Mycobacterium abscessus in Mice

Authors
 Thomas Dick  ;  Sung Jae Shin  ;  Won-Jung Koh  ;  Véronique Dartois  ;  Martin Gengenbacher 
Citation
 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol.64(2) : e01943-19, 2020-01 
Journal Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN
 0066-4804 
Issue Date
2020-01
MeSH
Animals ; Anti-Bacterial Agents / chemistry ; Anti-Bacterial Agents / pharmacology* ; Clarithromycin / pharmacology ; Disease Models, Animal ; Drug Repositioning ; Female ; Humans ; Lung Diseases / drug therapy* ; Lung Diseases / microbiology ; Mice ; Mice, Inbred NOD ; Mycobacterium Infections, Nontuberculous / drug therapy* ; Mycobacterium Infections, Nontuberculous / microbiology ; Mycobacterium abscessus / drug effects* ; Rifabutin / chemistry ; Rifabutin / pharmacology*
Keywords
nontuberculous mycobacteria ; NTM ; rifamycin ; mouse model ; animal model
Abstract
There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc(scid)/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.
Files in This Item:
T9992020496.pdf Download
DOI
10.1128/AAC.01943-19
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers
Yonsei Authors
Shin, Sung Jae(신성재) ORCID logo https://orcid.org/0000-0003-0854-4582
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190271
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links